Tredje AP fonden reduced its holdings in Becton Dickinson and Co (NYSE:BDX) by 1.5% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,688 shares of the medical instruments supplier’s stock after selling 307 shares during the quarter. Tredje AP fonden’s holdings in Becton Dickinson and were worth $4,223,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also added to or reduced their stakes in the company. IndexIQ Advisors LLC acquired a new position in Becton Dickinson and in the fourth quarter valued at $25,000. Verus Capital Partners LLC acquired a new stake in Becton Dickinson and during the fourth quarter worth about $27,000. Pinnacle Financial Partners Inc. acquired a new stake in Becton Dickinson and during the fourth quarter worth about $31,000. Cedar Mountain Advisors LLC acquired a new stake in Becton Dickinson and during the fourth quarter worth about $42,000. Finally, Harwood Advisory Group LLC acquired a new stake in Becton Dickinson and during the first quarter worth about $50,000. Hedge funds and other institutional investors own 86.79% of the company’s stock.
NYSE:BDX traded up $0.31 during trading hours on Friday, reaching $239.25. 11,783,270 shares of the stock were exchanged, compared to its average volume of 1,932,654. The company has a quick ratio of 0.66, a current ratio of 0.98 and a debt-to-equity ratio of 0.80. The firm has a 50 day simple moving average of $253.35 and a 200-day simple moving average of $255.35. Becton Dickinson and Co has a 52 week low of $197.75 and a 52 week high of $286.72. The stock has a market capitalization of $64.79 billion, a P/E ratio of 72.06, a P/E/G ratio of 2.57 and a beta of 0.95.
Becton Dickinson and (NYSE:BDX) last released its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $2.32 by $0.23. Becton Dickinson and had a return on equity of 15.75% and a net margin of 6.10%. The company had revenue of $4.25 billion for the quarter, compared to the consensus estimate of $4.10 billion. During the same quarter last year, the business posted $2.59 EPS. Becton Dickinson and’s quarterly revenue was up 1.4% compared to the same quarter last year. As a group, analysts expect that Becton Dickinson and Co will post 10.5 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 1.32%. The ex-dividend date of this dividend is Monday, June 8th. Becton Dickinson and’s dividend payout ratio is presently 27.05%.
BDX has been the subject of several research analyst reports. Raymond James upped their price target on Becton Dickinson and from $283.00 to $290.00 and gave the stock an “outperform” rating in a research note on Friday, May 8th. SVB Leerink restated a “market perform” rating and set a $262.00 price target (up from $245.00) on shares of Becton Dickinson and in a research note on Friday, May 8th. Stifel Nicolaus upped their price target on Becton Dickinson and from $265.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Morgan Stanley dropped their price target on Becton Dickinson and from $271.00 to $255.00 and set an “equal weight” rating for the company in a research note on Friday, March 27th. Finally, TheStreet lowered Becton Dickinson and from a “b” rating to a “c+” rating in a research note on Monday, March 9th. Nine research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $275.79.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
See Also: What is the return on assets formula?
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.